Cellectar Biosciences, Inc.
CLRB
$3.17
-$0.09-2.62%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -61.26% | -70.29% | -42.63% | -39.47% | 35.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -55.35% | -63.60% | -55.94% | -46.67% | 1.57% |
| Operating Income | 55.35% | 63.60% | 55.94% | 46.67% | -1.57% |
| Income Before Tax | -131.29% | 69.70% | -492.55% | 75.21% | 71.17% |
| Income Tax Expenses | -- | -- | -- | -- | 210.00% |
| Earnings from Continuing Operations | -124.81% | 69.70% | -492.55% | 75.21% | 70.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -124.81% | 69.70% | -492.55% | 75.21% | 70.11% |
| EBIT | 55.35% | 63.60% | 55.94% | 46.67% | -1.57% |
| EBITDA | 55.50% | 63.81% | 56.14% | 46.74% | -1.59% |
| EPS Basic | 23.51% | 87.43% | -339.78% | 84.21% | 89.27% |
| Normalized Basic EPS | 21.30% | 87.43% | -339.75% | 84.21% | 89.65% |
| EPS Diluted | 23.51% | 88.38% | 37.54% | 84.21% | 89.34% |
| Normalized Diluted EPS | 21.30% | 87.29% | -359.81% | 84.21% | 89.65% |
| Average Basic Shares Outstanding | 193.89% | 141.15% | 34.74% | 57.02% | 178.60% |
| Average Diluted Shares Outstanding | 193.89% | 138.37% | 28.89% | 57.02% | 178.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |